Advertisement

Topics

Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

11:38 EDT 14 Mar 2018 | Drug Discovery Development

AbbVie, in cooperation with Neurocrine Biosciences, Inc., announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.
Contributed Author: 

Original Article: Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids

NEXT ARTICLE

More From BioPortfolio on "Positive Topline Results from Second Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...